% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Beckmann:281352,
      author       = {Beckmann, Janna and Petzold, Moritz and Betzler, Felix and
                      Ströhle, Andreas and Bendau, Antonia and Dusemund, Carla
                      and Petzold, Gabor C and Meisel, Andreas and Hoffmann,
                      Sarah},
      title        = {{A}nxiety in {M}yasthenia {G}ravis {P}atients {T}hroughout
                      the {COVID}-19 {P}andemic-{P}revalence, {R}isk {F}actors,
                      and {A}ssociation {W}ith {V}accination {S}tatus.},
      journal      = {Brain and behavior},
      volume       = {15},
      number       = {9},
      issn         = {2162-3279},
      address      = {Malden, Mass.},
      publisher    = {Wiley},
      reportid     = {DZNE-2025-01099},
      pages        = {e70878},
      year         = {2025},
      abstract     = {A high prevalence of COVID-19-related anxiety was observed
                      among the general population during the COVID-19 pandemic.
                      Patients with myasthenia gravis (MG) might be at higher risk
                      for COVID-19-related anxiety due to immunosuppressive
                      therapy in the majority of cases and risk of myasthenic
                      exacerbation in case of an infection. This prospective
                      longitudinal study assessed COVID-19-related anxiety in MG
                      patients over 2 years of the pandemic and its association
                      with MG-specific factors (e.g., disease severity,
                      immunosuppressive medication) and with vaccination status.A
                      three-wave longitudinal online survey was conducted from May
                      2020 to February 2022, including a total of 648 adult MG
                      patients. Descriptive, univariate, and multivariate analyses
                      were performed to assess COVID-19-related and MG-related
                      anxiety, associated MG-specific factors, and association
                      with vaccination status.COVID-19-related anxiety was
                      frequent, with the most pronounced fear being risk for one's
                      own health (overall $83.9\%).$ Anxiety was influenced by MG
                      diagnosis (overall $75.1\%),$ especially by fear of
                      exacerbation of myasthenic symptoms and greater risk of
                      infection due to immunosuppressive therapy. Female sex and
                      treatment with immunosuppressive medication, including
                      rituximab, were associated with an increased concern for
                      one's own health. Fear for one's own health was the only
                      factor associated with vaccination status.COVID-19-related
                      anxiety was prevalent among MG patients. An ongoing
                      psychological impact is likely and highlights the need for
                      anxiety screening in clinical practice. Our findings
                      emphasize the importance of addressing mental health
                      challenges during future pandemics.},
      keywords     = {Humans / Myasthenia Gravis: psychology / Myasthenia Gravis:
                      epidemiology / Myasthenia Gravis: drug therapy / Myasthenia
                      Gravis: complications / COVID-19: psychology / COVID-19:
                      epidemiology / Female / Male / Anxiety: epidemiology /
                      Anxiety: etiology / Anxiety: psychology / Middle Aged / Risk
                      Factors / Prevalence / Adult / Aged / Longitudinal Studies /
                      Prospective Studies / Vaccination: psychology / Vaccination:
                      statistics $\&$ numerical data / Immunosuppressive Agents:
                      therapeutic use / Immunosuppressive Agents: adverse effects
                      / SARS-CoV-2 / autoimmune disease (Other) / corona (Other) /
                      fear (Other) / immunosuppressive treatment (Other) /
                      Immunosuppressive Agents (NLM Chemicals)},
      cin          = {AG Petzold},
      ddc          = {610},
      cid          = {I:(DE-2719)1013020},
      pnm          = {353 - Clinical and Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-353},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40958409},
      pmc          = {pmc:PMC12441002},
      doi          = {10.1002/brb3.70878},
      url          = {https://pub.dzne.de/record/281352},
}